Heterocyclic derivatives and use thereof

A compound selected from the group consisting of a heterocyclic derivative represented by formula (I), and a pharmaceutically acceptable salt and a stereoisomer thereof:

• wherein
• A is present or absent, and, if present, A is a saturated or unsaturated C3-10 carbocycle or a 5- to 10-membered heterocycle, and if A is absent, X3 and X4 are each independently optionally substituted with R1 or R2;
• B is a benzene or a 5- to 12-membered heterocycle;
• C is a benzene, a 5- to 12-membered heterocycle, or C3-6 carbocycle;
• Y is —C(═O)— connected to X2 or X5;
• X1 is —O—, —S—, —S(═O)—, —S(═O)2—, or —N(W1)—;
• X2 is a carbon atom connected to Y, or —N═, —NH—, —C(W2)═ or —CH(W2)— not connected to Y;
• X3 and X4 are each independently a carbon or nitrogen atom;
• X5 is a carbon atom connected to Y, or —CH═ not connected to Y;
• wherein the 5-membered ring comprising X1 to X5 is aromatic or non-aromatic;
• W is hydrogen, halogen, C1-6 alkyl, or 5- or 6-membered heterocyclyl-C1-3 alkyl;
• W1 is hydrogen, C1-6 alkyl, C1-6 alkoxycarbonyl, or 5- to 8-membered heterocyclyl-C1-4 alkyl;
• W2 is hydrogen, halogen, C1-6 alkyl, or 5- to 8-membered heterocyclyl-C1-4 alkyl;
• L is —(CR9R10)m—, —(CR9R10)m—O—, —NH—, —N(C1-6 alkyl)-, —S(═O)2—, —C(CH2)—, or C3-7 cycloalkylene, wherein m is an integer of 0 to 3, and R9 and R10 are each independently hydrogen, hydroxy, halogen, or C1-6 alkyl;
• R1 is nitro, amino, C1-6 alkylsulfonyl, haloC1-6 alkoxy, or any one of the following structural formulae i) to iv):
• R2 is hydrogen, halogen, nitro, amino, C1-6alkoxy, haloC1-6 alkoxy, C1-6 alkylsulfonyl, or 5- or 6-membered heterocycloalkyl;
• R3 is hydrogen, halogen, cyano, C1-6 alkyl, haloC1-6 alkyl, cyanoC1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkoxy, haloC1-6 alkoxy, cyanoC1-6 alkoxy, C1-6 alkylamino, diC1-6 alkylamino, C1-6 alkylthio, C1-6 alkylaminocarbonyl, diC1-6 alkylaminocarbonyl, C2-8 alkynyl, C6-10 aryl, haloC6-10 aryl, 5- to 10-membered heterocyclyl, or 5- to 10-membered heterocyclylcarbonyl, wherein the heterocyclyl moiety is optionally substituted with one to three substituents selected from the group consisting of halogen, hydroxy, cyano, amino, C1-6 alkyl, haloC1-6 alkyl, C1-6 alkoxy and C1-6 alkoxycarbonyl;
• R4 is hydrogen, halogen, hydroxy, cyano, nitro, amino, oxo, aminosulfonyl, sulfonylamido, C1-6 alkylamino, C1-6 alkyl, haloC1-6 alkyl, cyanoC1-6 alkyl, C1-6 alkoxy, haloC1-6 alkoxy, cyanoC1-6 alkoxy, C3-8cycloalkyl-oxy, C2-8 alkynyl, C1-6 alkylamino-C1-6 alkoxy, diC1-6 alkylamino-C1-6 alkoxy, C1-6 alkoxy-carbonyl, carbamoyl, carbamoyl-C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, 5- to 10-membered heterocyclyl, 5- to 10-membered heterocyclyl-C1-6 alkyl, 5- to 10-membered heterocyclyl-C1-6 alkoxy, or 5- to 10-membered heterocyclyl-oxy, wherein the heterocyclyl moiety is optionally substituted with one or two substituents selected from the group consisting of hydroxy, oxo, C1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylsulfonyl, diC1-3 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminocarbonyl, diC1-3 alkylaminocarbonyl, C1-6 alkylaminosulfonyl, and non-substituted or C1-6 alkyl-substituted 5- to 10-membered heterocyclyl;
• R5 is hydrogen, C1-6 alkyl, carbamoylC1-6 alkyl, C1-6 alkylaminoC1-6 alkyl, diC1-6 alkylaminoC1-6 alkyl, or 5- to 10-membered heterocyclylC1-6 alkyl, or is fused with R6 to form C3-4 alkylene;
• R6 is C1-6 alkyl, haloC1-6 alkyl, C1-6 alkoxyC1-6 alkyl, C1-6 alkylcarbonylC1-6 alkyl, C2-7 alkenyl, amino, aminoC1-6 alkyl, C3-7 cycloalkyl, 5- to 10-membered heterocyclyl, or 5- to 10-membered heterocyclyl-C1-6 alkyl, or is fused with R5 to form C3-4 alkylene, wherein the amino moiety is optionally substituted with one or two substituents selected from hydroxy or C1-6 alkyl, and the heterocyclyl moiety is optionally substituted with one to four substituents selected from the group consisting of oxo, C1-6 alkyl and C1-6 alkylcarbonyl;
• R7 and R8 are each independently hydrogen or C1-6 alkyl;
• p and q are each independently 0 or 1;
• r is an integer of 0 to 3, and, when r is 2 or higher, R3 moieties are the same or different;
• and
• s is an integer of 0 to 3, and, when s is 2 or higher, R4 moieties are the same or different;
• all of said heterocycle or heterocyclyl moieties each independently have a saturated or unsaturated single or multiple ring and contain one to three heteroatoms selected from N, O or S;
• and
• all of said aryl moieties each independently have an aromatic single or multiple ring.